SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
21Shares US LLC filed a Third Amended and Restated Trust Agreement for the 21Shares Dogecoin ETF with Wilmington Trust, N.A. dated August 26, 2026, outlining the management and tax…
By amending Delaware law to allow action by written consent, Tevogen enhances operational flexibility. The change to Article VII, Section 7.01 is effective immediately upon filing.
The FDA has approved Rasonque, a targeted therapy for advanced pancreatic cancer, months ahead of schedule, delivering a novel treatment option after months of regulatory review.
The company filed an amended and restated certificate of incorporation to update its bylaws and governance structure. This regulatory filing provides a foundation for current busin…
Ivonescimab plus chemotherapy showed statistically significant overall survival superior to Durvalumab plus chemo in the advanced biliary tract cancer Phase III HARMONi-GI1 trial, …
Celcuity submitted a supplemental New Drug Application to the FDA for REVTORPYK targeting breast cancer patients with a PIK3CA mutation. Market relevance: If approved, it could bec…
Kraft Heinz will move its listing to the NYSE and commence trading on September 14, 2026, under ticker symbol KHC, marking a milestone in its transformation.
BDO USA consented to incorporate its audit report in the company's registration statements, providing assurance on the financial statements.
BeOne Medicines Ltd. filed its 2026 STAR interim report for the six months ended June 30, 2026, detailing research and development expenses allocated by key products in accordance …
The FDA approved the Libre Duo system for continuous monitoring of both blood sugar and ketone levels in people aged two and older living with diabetes.
The Federal Reserve published minutes from the July 20 and July 29, 2026 board meetings regarding the discount rate.
The primary endpoint for TD-9855 was not statistically significant, though secondary trends showed some improvement. The company stated the drug was generally well-tolerated and re…
Zymeworks announced the FDA approved a Ziihera plus tislelizumab and chemotherapy regimen for first-line HER2-positive gastroesophageal adenocarcinoma, boosting its diversified col…
Endovia Health Sciences, formerly Splash Beverage, received Investigational New Animal Drug (INAD) status for its veterinary cancer pain treatment CannEpil, marking its first regul…
Anavex Life Sciences reported financial results for Q3 2026 and submitted completed AD clinical data to the FDA, with upcoming IND submissions for Rett Syndrome and Fragile X Syndr…
Incannex announced the first patient dosing in the DReAMzz Phase 2 dose-optimization study for IHL-42X, a treatment for obstructive sleep apnea expected to further support the Phas…
Regulatory authorities placed a clinical hold on RGX-121 for Hunter Syndrome as asymptomatic spine nodules were discovered; the company anticipates limited near-term shareholder va…
America Great Health published an interim summary of a clinical observational study finding acceptable outcomes for ion-modified peptide adjunctive therapy in solid tumor patients.…
Tenon Medical Inc. regained compliance with Nasdaq's $1.00 minimum bid price requirement following its 1-for-35 reverse stock split, avoiding potential delisting. The recovery indi…
The registrant filed an 8-K to report that Liberty Island Group I, LLC, a sponsor, filed for bankruptcy protection on August 11, 2026. This event is relevant as it affects the spon…